Ultrasound scans ofa patient showing(left) a normal gall bladder before treatment and (right) multiple tiny gall stones after 12 months' treatment. These were mobile on real time scans and showed acoustic shadowing there have been only isolated reports of gall stones occurring during octreotide treatment.' Gall bladder contraction and cholecystokinin secretion in response to food are almost abolished by its administration4 and may contribute to stone formation. The high incidence of gall stones might have been due to the higher doses of the drug which we used. None of our patients had symptoms from the gall stones, and the correct management of the stones remains problematical.5 While further prospective studies of the incidence of gall stones during octreotide treatment are awaited we recommend the use of the smallest effective dose of octreotide. Clinical Gerontology Unit,
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Methods
We used data from the Office of Population Censuses and Surveys for England and Wales in 1985 that were stratified by sex and age' to calculate the expected numbers of deaths from coronary heart disease over five years. We assumed that they had been screened and that drugs had been prescribed over five years for all people with concentrations -6 5 mmol/l, and that compliance was 100%. We used prevalences of cholesterol concentrations -6 5 mmol/I obtained from the Scottish Monica survey4 and relative risks approximated from prospective studies5 to estimate the number of deaths from coronary heart disease over five years in people with cholesterol concentrations -6 5 mmolUl. We then calculated the number of deaths that would have been prevented if all people with such concentrations had been treated, assuming a 20% reduction in mortality from coronary heart disease in all age and sex groups.
We then derived prevalences of cholesterol concentrations : 6-5 mmol/l specific to age and sex assuming that the mean cholesterol concentration in the population was decreased by 0 5 mmol/1,3 and, assuming that mortality was the same in people with each cholesterol concentration, estimated the potential reduction in numbers of deaths from coronary heart disease with these prevalences.
Results and Comment
Even assuming a fixed relative risk for high cholesterol concentrations and a fixed relative benefit for treatment in people in all age and sex groups, the absolute benefit of screening for individual people and the community varies enormously. For individual people the absolute benefit depends on the incidence of coronary heart disease, for which age and sex are important determinants. To prevent one death from coronary heart disease within five years estimates of the numbers of people who would have to be screened over the five years and of those who would subsequently be treated ranged from 137 320 and 20 600 respectively for
Estimates ofpotential benefits of cholesterol screening and subsequent treatment for preventing deaths from coronary heart disease in population ofEngland and Wales in 1985' according to age and sex.
